Last reviewed · How we verify
SIM0417
At a glance
| Generic name | SIM0417 |
|---|---|
| Also known as | Simnotrelvir |
| Sponsor | Jiangsu Simcere Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- To Evaluate SSD8432/ Ritonavir in Adults With COVID-19 (PHASE1, PHASE2)
- A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19 (PHASE2, PHASE3)
- Safety and Pharmacokinetics of SIM0417 Combined With Ritonavir in Healthy Elderly Subjects (PHASE1)
- Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir (PHASE1)
- Drug-Drug Interaction Study of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy Participants (PHASE1)
- Study to Investigate the Mass Balance and Biotransformation of SIM0417 in Healthy Adult Chinese Male Participants (PHASE1)
- Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical Study (PHASE2)
- To Evaluate SSD8432/Ritonavir in Adults With COVID-19 (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SIM0417 CI brief — competitive landscape report
- SIM0417 updates RSS · CI watch RSS
- Jiangsu Simcere Pharmaceutical Co., Ltd. portfolio CI